Platelet inhibiting drugs

Platelet transfusions have limited utility in eptifibatide-related hemorrhage as new platelets are inhibited by the circulating drug. No

Antiplatelet agents are drugs that inhibit enzymes or receptors required for platelet activation, platelet aggregation, and/or thrombus

The most commonly used drug that inhibits platelet function is aspirin, which inhibits cyclooxygenase I (COX-1) conversion of arachidonic acid to thromboxane A 2, inhibiting platelet function by preventing the enhancement and propagation of agonist-induced platelet signaling. Additional drugs that inhibit platelet COX-1 include nonspecific

Antiplatelet drugs are primarily directed against platelets and inhibit platelet activation by a number of different mechanisms. They are used for the

Antiplatelet drugs are primarily directed against platelets and inhibit platelet activation by a number of different mechanisms.

Antiplatelet agents are drugs that inhibit enzymes or receptors required for platelet activation, platelet aggregation, and/or thrombus

Antiplatelet drugs inhibit platelet release and aggregation and prevent platelet formation in the blood. When platelet aggregation is prohibited

Mechanism: Possibly via inhibition of serotonin-mediated platelet activation (inhibition of the serotonin reuptake transporter) and subsequent platelet

Antiplatelet drugs can reversibly or irreversibly inhibit process involved in platelet activation resulting in decreased tendency of platelet